137 related articles for article (PubMed ID: 35781075)
1. Evaluation of PEG-L-asparaginase in asparagine suppression and anti-drug antibody development in healthy Beagle dogs: A multi-phase preclinical study.
Feenstra LR; Gehring R; van Geijswijk IM; König T; Prinsen HCMT; Vandemeulebroecke K; Lammens T; Krupa A; Teske E
Vet J; 2022 Aug; 286():105854. PubMed ID: 35781075
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
MacEwen EG; Rosenthal RC; Fox LE; Loar AS; Kurzman ID
J Vet Intern Med; 1992; 6(4):230-4. PubMed ID: 1522554
[TBL] [Abstract][Full Text] [Related]
3. A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma.
MacEwen EG; Rosenthal R; Matus R; Viau AT; Abuchowski A
Cancer; 1987 Jun; 59(12):2011-5. PubMed ID: 3567863
[TBL] [Abstract][Full Text] [Related]
4. Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma.
Teske E; Rutteman GR; van Heerde P; Misdorp W
Eur J Cancer; 1990; 26(8):891-5. PubMed ID: 2145933
[TBL] [Abstract][Full Text] [Related]
5. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
Panetta JC; Gajjar A; Hijiya N; Hak LJ; Cheng C; Liu W; Pui CH; Relling MV
Clin Pharmacol Ther; 2009 Dec; 86(6):651-8. PubMed ID: 19741605
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.
Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
Cancer Chemother Pharmacol; 1993; 32(4):310-4. PubMed ID: 8324873
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Kim HJ; Ock CY; Kim TM; Lee SH; Lee JY; Jung SH; Cho YS; Kim M; Keam B; Kim DW; Kim IH; Heo DS
Cancer Res Treat; 2018 Jul; 50(3):670-680. PubMed ID: 28675023
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors.
Taylor CW; Dorr RT; Fanta P; Hersh EM; Salmon SE
Cancer Chemother Pharmacol; 2001; 47(1):83-8. PubMed ID: 11221967
[TBL] [Abstract][Full Text] [Related]
9. Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase.
Kidd JA; Ross P; Buntzman AS; Hess PR
Vet Comp Oncol; 2015 Jun; 13(2):77-88. PubMed ID: 23253146
[TBL] [Abstract][Full Text] [Related]
10. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
11. Neutropenia associated with vincristine and L-asparaginase induction chemotherapy for canine lymphoma.
Northrup NC; Rassnick KM; Snyder LA; Stone MS; Kristal O; Cotter SM; Moore AS
J Vet Intern Med; 2002; 16(5):570-5. PubMed ID: 12322708
[TBL] [Abstract][Full Text] [Related]
12. Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Cawley JR; Wright ZM; Meleo K; Post GS; Clifford CA; Vickery KR; Vail DM; Bergman PJ; Thamm DH
J Vet Intern Med; 2020 Mar; 34(2):882-889. PubMed ID: 32064697
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
[TBL] [Abstract][Full Text] [Related]
14. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
[TBL] [Abstract][Full Text] [Related]
15. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
16. Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients.
Wu J; Chen C; Huang S; Shen S; Chen J; Zhang S
Technol Cancer Res Treat; 2020; 19():1533033820980113. PubMed ID: 33287663
[TBL] [Abstract][Full Text] [Related]
17. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
18. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
19. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
20. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?
MacDonald VS; Thamm DH; Kurzman ID; Turek MM; Vail DM
J Vet Intern Med; 2005; 19(5):732-6. PubMed ID: 16231719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
